Background: A large number of human tumor-associated antigens that are recognized by CD8
Introduction
One of the most promising approaches in cancer therapy relies on harnessing the immune system to eradicate malignant cells [1] , the success of which relies largely on the identification of suitable tumor-associated antigens (TAA) for generating effective cancer vaccines. It has been well-established that tumor cells express TAAs that can be recognized by CD8 + T cells in the context of human leukocyte antigen class I (HLA-I) molecules. A large number of TAAs and TAA-derived epitopes have been identified [2, 3] , with some of these proteins and peptide derivatives already in clinical vaccine trials. Recent approvals of the immunotherapybased vaccine/drug sipuleucel-T (Provenge) and ipilimumab (Yervoy) by the Food and Drug Administration (FDA) represent milestones in the field of cancer immunotherapy [4, 5] . And a phase III clinical trial of the gp100 peptide for melanoma also yielded highly encouraging results [6] . In addition, work from two independent groups underlined the importance of tumor-specific antigens in eliciting immune responses against a developing tumor [7, 8] , undoubtedly further intensifying the efforts to search for novel tumor antigens for cancer immunotherapy.
Despite such promising results, success in cancer vaccine trials on the whole has been sporadic [9] [10] [11] . During the last couple of years, several TAAs that are expressed in different types of neoplasia have been identified [2, 3] . However, the majority of the antigens described thus far are dispensable for the survival and growth of the tumor cells, with the exception of a few TAAs such as telomerase [12] , survivin [13] and anti-apoptotic members of the Bcl-2 family (Bcl-2, Bcl-X(L) and Mcl-2) [14] . Tumor cells may therefore have escaped surveillance by the immune system through loss and/or down-regulation of tumor antigens [15] . Consequently, targeting TAAs that are essential for survival and growth of tumor cells may better prevent immunoselection of antigen-loss variants as a result of vaccination and improve the efficacy of cancer immunotherapy [15, 16] . Such immunogenic tumor antigens that elicit minimal immune escape therefore represent the most optimal vaccine candidates for immunotherapy of cancer.
Special AT-rich sequence binding protein 1 (SATB1) is a nuclear factor that functions as a global chromatin organizer. It regulates gene expression by folding chromatin into loop domains, and tethering DNA domains to the SATB1 network structure [17] . SATB1 appeared to be over-expressed in aggressive breast cancer cell lines but absent or undetectable in normal and immortalized human mammary epithelial cells, suggesting a role of SATB1 in reprogramming chromatin organization and ultimately transcriptional profiles of breast tumors to promote growth and metastasis [18] . In addition, higher levels of SATB1 expression were associated with many other types of cancer, including laryngeal squamous cell carcinoma [19] , endometrioid endometrial cancer [20] , hepatocellular carcinoma [21] , rectal cancer [22] , cutaneous malignant melanoma [23] , gastric cancer [24, 25] , ovarian cancer [26] , prostate cancer [27] , lung cancer [28] and glioma [29] . Up-regulation of SATB1 in these types of cancers can promote tumor growth and metastasis. Since SATB1 is essential for tumor growth/survival and metastasis, immune escape by loss or down-regulation of SATB1 expression may impair sustained tumor cell growth and/or metastasis, thus making SATB1 an attractive target for anticancer vaccines against various types of cancers that express SATB1.
In this report, we describe the identification of SATB1-derived T cell epitopes for T cell recognition using an immunobioinformatics approach. We selected twelve peptides that were predicted to bind to the HLA-A*02 molecule. They were synthesized and evaluated in vitro for their ability to stimulate T cells in PBMCs from healthy subjects and/or cancer patients based on interferon-c (IFN-c) release. One of these peptides, SATB1 565-574 , was found to induce IFN-c release in peripheral T cells from both healthy subjects and cancer patients. Importantly, SATB1 565-574 -specific T cells were able to recognize and kill HLA-A*02 + , SATB1-expressing tumor cells in an HLA-I-dependent manner. These results demonstrate the validity of the immuno-bioinformatics approach and suggest SATB1 565-574 may represent a new tumor-specific epitope for cancer immunotherapy.
Materials and Methods

Healthy Donors and Cancer Patients
HLA-A*02 + prostate or ovarian cancer patients and ten HLA-A*02 + healthy subjects were enrolled in this study after written informed consent was obtained. All protocols were approved by the Institutional Review Board (IRB) at the Baylor College of Medicine prior to commencing studies. 20 mL of peripheral blood was obtained from each person, and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Lymphoprep (Nycomed Pharma AS; Oslo, Norway). Freshly isolated PBMCs were cryopreserved for later use in 1 mL freezing medium containing 90% FCS and 10% dimethyl sulfoxide (DMSO) at 2140uC. HLA-A*02 expression in PBMCs obtained from cancer patients and healthy subjects was verified by flow cytometry with FITC-labeled HLA-A*02 mAb BB7.2 (BD Pharmingen; San Diego, CA, USA).
Cell Lines
All breast cancer cell lines (MCF-7, CAMA-1, MDA-MB-134VI, MDA-MB-175VII, MDA-MB-361, DU4475, MDA-MB-231, MDA-MB-436, MDA-MB-453, MDA-MB-468), T2 cells (an  HLA-A*02 + TAP-deficient cell line), prostate cancer cell lines (PC3, LNCaP and DU145), ovarian cancer cell line Ovcar-3 and lymphoma cell line Jeko-1 were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). An ovarian cancer cell line Skov-1 [30, 31] was a gift from Dr. Kunle Odunsi (Roswell Park Cancer Institute, NY, USA); a lymphoma cell line L1236 [32, 33] was a gift from Dr. Catherine M. Bollard (Baylor College of Medicine, Houston, USA). All cell lines were maintained in RPMI-1640 medium (Mediatech; Manassas, VA, USA), supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin and streptomycin.
Peptides
Twelve SATB1-derived peptides (Table 1) were predicted using BIMAS (http://www-bimas.cit.nih.gov/molbio/hla_bind/), SYF-PEITHI (http://www.syfpeithi.de/), and Rankpep (http://bio. dfci.harvard.edu/Tools/rankpep.html) based on the HLA-A*02 binding motif. Epitopes that were predicted by at least two of these algorithms were selected for further testing. The peptides were synthesized by a solid-phase method using a peptide synthesizer (AApptec, Inc.; Louisville, KY, USA), purified by reverse-phase high-performance liquid chromatography and validated by mass spectrometry. The synthesized peptides were dissolved in DMSO at a concentration of 10 mg/mL and stored at 280uC until further use. One peptide (SATB1 544-552 ) was excluded from the study due to the difficulty of peptide synthesis.
In vitro Stimulation of Peptide-specific T Cells in PBMCs
PBMCs (1610 5 cells/well) from either healthy subjects or cancer patients were incubated with standard peptide concentrations of 20 mg/mL per peptide [34] [35] [36] [37] in 96-well U-bottom microplates (BD; Franklin Lakes, NJ, USA) in 200 mL of T-cell medium (TCM), consisting of RPMI 1640 (Mediatech; Manassas, VA, USA), 10% human AB serum (Valley Biomedical, Winchester, USA), 50 mM of 2-mercaptoethanol, 100 IU/mL of interleukin-2 (IL-2), and 0.1 mM MEM nonessential amino acid solution (Invitrogen; grand island, NY, USA). Half of the TCM was removed and replaced with fresh TCM containing peptides (20 mg/mL) every 5 days. After 14 days of culture, the cells were harvested and tested for their ability to produce IFN-c in response to T2 cells (1610 4 cells/well), which were pre-loaded with either SATB1 peptide (5 mg/mL) or a control peptide (an irrelevant HLA-A*02 binding EBV peptide: GLCTLVAML ) as a negative control. After 18 hours of incubation, supernatants were collected, and IFN-c release was determined by ELISA assay.
Rapid Expansion Protocol (REP) for SATB1 Peptidespecific T Cells SATB1 peptide-specific T cells were expanded by a rapid expansion protocol (REP) as previously described [38] with a slight modification. Briefly, on day 0, 0.1-0.5610 6 SATB1 peptidespecific T cells were cultured in a T25 flask with 20 mL RPMI-1640 supplemented with 10% human AB serum, 50 mM of 2-mercaptoethanol, 30 ng/mL OKT3 antibody (Ortho Biotech; Bridgewater, NJ, USA) and 30 ng/mL anti-CD28 antibody (R&D Systems; Minneapolis, MN, USA), together with 20610 6 irradiated allogeneic PBMCs and 5610 6 irradiated Epstein Barr Virus (EBV) transformed B cells as feeder cells. Flasks were incubated upright at 37uC in 5% CO 2 . IL-2 (300 IU/mL) was added on day 1, and on day 5, half of the cell culture supernatant was removed and replenished with fresh medium containing 300 IU/mL IL-2. 14 days after initiation of the REP, cells were harvested and cryopreserved for future experiments.
Depletion of CD4
+ or CD8 + T Cells from PBMCs 
ELISA Assay
Cytokine release was measured by coating 96-well ELISA plates (Thermo Fisher Scientific; Rochester, NY, USA) with 1 mg/mL anti-human IFN-c (Pierce Biotechnology; Rockford, IL, USA) overnight at 4uC. The plate was washed six times with PBS containing 0.05% Tween-20 (wash solution) to remove unbound coating antibody, and blocked with 1% BSA/PBS at room temperature for 2 hrs. Afterwards, 50 mL supernatant was added to each well and incubated at room temperature for 1 hr, then 50 mL of 0.5 mg/mL biotinylated anti-human IFN-c (Pierce Biotechnology; Rockford, IL, USA) was added and plates were incubated for an additional 1 hr at room temperature. After incubation, plates were washed and incubated for 30 min with Poly-HRP-Streptavidin (Thermo Fisher Scientific; Rochester, NY, USA) diluted 1:5000 in PBS/1% BSA. Plates were washed and 100 mL of TMB substrate solution (Sigma-Aldrich Co.; St. Louis, MO, USA) was added per well. The colorimetric reaction was stopped using 2N H 2 SO4 and plates were read at 450 nm using an ELISA plate reader.
RNA Extraction and RT-PCR
RNA extraction and RT-PCR was carried out as reported previously [39] . In brief, total RNA was extracted from cancer cells with 1 mL Trizol reagent (Invitrogen; Carlsbad, CA, USA). Three micrograms of RNA was reverse-transcribed to cDNA in 30 ml volume and 1 ml of each cDNA was used in subsequent PCR reaction with a pair of SATB1 specific primers: Primer 1:59-TGCAAAGGTTGCAGCAACCAAAAGC-39; 59-AACATGGA-TAATGTGGGGCGGCCT-39. GAPDH was used as loading control: primer 1:59-TGATGACATCAAGAAGGTGGTGAAG-39; Primer 2:59-TCCTTGGAGGCCATGTGGGCCAT-39. The PCR reaction was carried out under the following conditions: 95uC for 1 min, 95uC for 40 s, 60uC for 30 s, 72uC for 40 s, total 40 cycles, 72uC for 5 min, and GAPDH was run for 25 cycles. Equal amounts of PCR products were then loaded and detected by gel electrophoresis.
Western Blot
Whole cell extracts were prepared and resolved in SDS-PAGE gels. The proteins were transferred to PVDF membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and further incubated with the SATB1 antibody (BD Biosciences, San Jose, CA, USA). LumiGlo Chemiluminescent Substrate System from KPL (Gaithersburg, MD, USA) was used for protein detection.
FACS Analysis
Cells (0.5610 6 ) were stained with either FITC-anti-CD8, PECy5-anti-CD4 (Both from eBioscience, San Diego, CA, USA) or FITC-anti-HLA-A*02 (BD Pharmingen; San Diego, CA, USA) in PBS containing 2% FBS on ice for 30 min, and then washed twice in PBS. Afterwards, cells were re-suspended in 500 ml PBS and analyzed using a FACScalibur machine. For DimerX HLA-A*02:Ig staining, SATB1 reactive CD8 + T cells were incubated with purified HLA-A*02:Ig dimer (BD Biosciences, San Jose, CA, USA) loaded with a given peptide, and then stained with FITC anti-mouse IgG1 (BD Biosciences, San Jose, CA, USA). Flow cytometry was performed on a FACScalibur machine.
Cytotoxicity Assay
SATB1-derived peptide-specific T cells were tested for cytotoxicity against peptide-loaded T2 cells, two HLA-A*02 + SATB1 + cancer cell lines (Skov-1 and Jeko-1) and an HLA-A*02 negative SATB1 + PC3 cell line as a negative control by a lactate dehydrogenase (LDH) assay (Promega; Madison, WI, USA). The assay was performed in accordance with the manufacturer's instructions. LDH release was calculated based on the following formula:
Cytotoxicity (%) = (Experimental -Effector SpontaneousTarget Spontaneous LDH release)/(Target Maximum -Target Spontaneous LDH release)6100.
Spontaneous release was determined by using the supernatant of the target cells alone or effector cells alone, and the maximum release was determined by using the supernatant of target cells incubated with a lysis solution included in LDH kit. 
Results
SATB1 mRNA is Expressed in a Variety of Cancers
To examine whether SATB1 is expressed in cancer cells, mRNA expression for SATB1 in various types of tumor cells was performed by RT-PCR. As shown in Figure 1 , SATB1 mRNA was highly expressed in a variety of cancers including breast cancer, ovarian cancer, prostate cancer as well as lymphoma. While the normal prostate epithelial cell line, PNT1A did not express SATB1 mRNA.
Induction of SATB1-derived Peptide-specific CTLs in Healthy Donors
First, we obtained PBMCs from 10 HLA-A*02
+ healthy donors to determine whether SATB1-reactive T cell precursors were present in these healthy subjects. The cells were stimulated in vitro for two weeks with each of the SATB1-derived peptides containing HLA-A*02-binding motif (Table 1) . At the end of peptide stimulation, supernatants from the cultures were analyzed by ELISA to detect IFN-c release in response to T2 cells pulsed with or without corresponding peptides. As shown in Table 2 , nearly all of the 11 SATB1-derived peptides (10/11) were capable of inducing peptide-specific T cell responses in at least one of the healthy subjects. In particular, the peptide SATB1 565-574 induced higher level of IFN-c release (.900 pg/mL) in 4 out of 10 healthy subjects, indicating its high immunogenicity and potential in expanding antigen-specific T cells in healthy subjects.
Presence of SATB1-derived Peptide Specific CTLs in Cancer Patients
Our analysis indicated that peptide-specific T cells against SATB1 565-574 were found in ,60% of healthy subjects, we therefore reasoned that CTL precursors that could recognize this peptide might also be abundant in PBMCs from cancer patients. To test our hypothesis, we examined whether peptide SATB1 565-574 could induce peptide-specific CTLs from PBMCs of HLA-A*02 + ovarian cancer patients. PBMCs from three HLA-A*02 + ovarian cancer patients were collected and stimulated in vitro with peptide SATB1 565-574 . As shown in Table 3 , peptide SATB1 565-574 was able to induce peptide-specific CTLs from PBMCs of ovarian cancer patients, indicating that the peptide is highly immunogenic not only in healthy subjects but also in cancer patients. We also determined whether this peptide candidate could induce peptide-specific CTLs from PBMCs of HLA-A*02 + prostate cancer patients. As was the case with ovarian cancer patients, peptide SATB1 565-574 similarly induced peptide-specific CTLs from PBMCs of 5 prostate cancer patients as well (Table 3) , indicating CTL precursors that recognize this peptide are abundant in PBMCs from cancer patients.
SATB1-derived Peptide Induced CD8 + T Cell-dependent Responses
To further analyze SATB1 565-574 peptide-specific T cells, we next expanded SATB1 565-574 peptide-specific T cells identified in Tables 2 and 3 in order to obtain a sufficient number of these cells. To this end, we performed peptide titration experiments to determine the optimal peptide concentration for loading T2 cells for T cell recognition. As shown in Figure 2A , T2 cells could be sensitized by peptide SATB1 565-574 but not a control EBV peptide for T cell recognition at a concentration of 0.08 mg/mL, and the binding sites of HLA-A*02 molecules on T2 cells became saturated at 5 mg/mL. Further increasing the concentrations of SATB1 565-574 failed to enhance production of IFN-c. Therefore, we consistently used the peptide concentration of 5 mg/mL for pre-loading T2 cells in our ELISA assays. The expanded T cells maintained antigen-specificity and secreted significant amounts of IFN-c after stimulation with T2 cells pulsed with the corresponding peptides, but not with a control EBV peptide (Figures 2A and  B) . To obtain direct evidence on the subsets of the responding T cells depicted in Figure 2B , the expanded SATB1 peptide-reactive PBMCs were depleted for either CD4 + T cells ( Figure 2C ) or CD8 + T cells ( Figure 2D ) prior to incubation with peptides for ELISA assays. As shown in Figure 2E Based on our results thus far, SATB1 565-574 specific CD8
+ T cells were used in subsequent experiments. To determine whether SATB1-derived peptide-specific T cells were able to recognize and kill HLA-A*02 + , SATB1-expressing cancer cells, we used an HLA-A*02 2 SATB1 mRNA positive prostate cancer cell line PC3 (as a negative control) and five HLA-A*02 + SATB1 mRNA positive cancer cell lines. The expression of SATB1 mRNA in these 6 cell lines was previously examined by RT-PCR ( Figure 1 ) and HLA-A*02 expression was verified by flow cytometry ( Figure 3A ). In addition, we also checked the expression of SATB1 protein among these cell lines ( Figure 3B) , and found that all cancer cell lines expressed SATB1 protein except PC3 and Ovcar-3. Therefore, Ovcar-3 was also regarded as a negative control. As shown in Figure 4A , SATB1 565-574 -specific T cells could recognize HLA-A*02 + SATB1 expressing Skov-1 and Jeko-1 cells, but not PC3 or Ovcar-3 cells. The other two HLA-A*02 + SATB1 expressing cancer cell lines (CAMA-1, MDA-MB-231) could only be recognized when they were pre-treated with IFN-c ( Figure 4B ), suggesting that either enhanced HLA-A*02 expression on the cell surfaces ( Figure S2 ) or induction of immunoproteasomes by IFNc, may facilitate the presentation of the correct epitope to cell surfaces for T cell scrutiny. In contrast, normal cells, including PNT1A and autologous PBMCs, could not be recognized by SATB1 565-574 -specific T cells ( Figure 4A ). In addition, SATB1 565-574 -specific T cells did not recognize in vitro-differentiated Th subsets, including Th1, Th2 and Th17 cells ( Figure S3 ).
To determine whether the recognition of cancer cells by SATB1 565-574 -specific CD8 + T cells was HLA-I restricted, we cocultured SATB1 565-574 -specific T cells with either Skov-1 or Jeko-1 cells in the presence of either anti-HLA-I mAb (W6/32) or anti-HLA-II mAb. As shown in Figure 4C and D, T cell responses were completely inhibited by the addition of anti-HLA-I mAb, but not anti-HLA-II (HLA-DP mAb), which suggests that the recognition of tumor cells by SATB1 565-574 -specific CD8 + T cells is HLA-I restricted.
To further examine whether SATB1 565-574 -specific CD8 + T cells were able to kill HLA-A*02 + , SATB1-expressing cancer cells, we performed cytotoxicity assays. As shown in Figure 4E , SATB1 565-574 -specific T cells killed T2 cells pulsed with SATB1 565-574, but not T2 cells alone or those pulsed with a control EBV peptide. Importantly, SATB1 565-574 -specific T cells were able to kill HLA-A*02 + , SATB1 expressing Skov-1 and Jeko-1 cells, but not HLA-A*02 2 PC3 cells ( Figure 4F and G). These results suggest that SATB1 565-574 -specific T cells recognize a T cell epitope that is endogenously processed and presented by tumor cells.
Discussion
It is well-established that CD8
+ T cells play a critical role in controlling tumor development and progression. Peptide epitopes derived from TAAs can be recognized as antigens by T cells in the context of MHC-I molecules [40, 41] . Identification of ideal TAAs and their peptides that are recognized by T cells are essential for the development of effective cancer vaccines. Ideal TAAs such as anti-apoptotic proteins [14] , telomerase [12] and survivin [13] , being mandatory for tumor growth/survival, may represent Table 2 . Recognition of the peptides by in vitro-stimulated T cells from the PBMCs of ten HLA-A*02 + healthy subjects. 
cells (E) or CD8
+ T cells (F) were determined by ELISA. SATB1 reactive CD8 + T cells were incubated with purified HLA-A2:Ig dimer loaded with a control EBV peptide (G) or with peptide SATB1 565-574 (H), and then stained with FITC anti-mouse IgG1. Cells were analyzed using a FACScalibur machine. Data (from A, B, E and F) are plotted as means 6 SD. Results are representative of at least three independent experiments. *P,0.05, **P,0.01, ***P,0.001 versus controls (T2 cells alone or T2 cells pulsed with a control EBV peptide). doi:10.1371/journal.pone.0056730.g002 optimal targets for vaccine mediated immunotherapy of cancer. SATB1 is highly expressed in many types of human cancers and up-regulation of SATB1 expression is essential for tumor survival and metastasis, thus SATB1 represents one of such ideal TAAs.
The aim of the current study was to identify HLA-A*02 binding SATB1-derived epitopes recognized by CD8 + T cells in PBMCs of healthy subjects and cancer patients. Twelve SATB1-derived peptides were predicted using BIMAS, SYFPEITHI, and Rankpep based on the HLA-A*02 binding motif. Peptides that were predicted by at least 2 of 3 programs were selected for further testing for their ability to stimulate PBMCs from healthy subjects and/or cancer patients. Further studies showed that 10 out of 11 synthesized SATB1-derived peptides were capable of inducing peptide-specific T cell responses in at least one out of 10 healthy subjects. Specifically, SATB1 565-574 was found to induce higher level of IFN-c release (.900 pg/mL) in 4 out of 10 healthy subjects, indicating that this peptide may be immunogenic and potentially capable of expanding antigen-specific T cells in healthy subjects. Furthermore, SATB1 565-574 induced frequently specific T cell responses in PBMCs of ovarian cancer patients as well as in PBMCs from prostate cancer patients. Importantly, SATB1 565-574 peptide-specific T cells recognized and killed HLA-A*02 + SATB1-expressing Jeko-1, Skov-1 cells as well as IFN-c-treated breast cancer cell lines (CAMA-1 and MDA-MB-231), suggesting this peptide is naturally processed by cancer cells.
SATB1 is a global chromatin organizer and transcription factor and has emerged as a key factor integrating higher-order chromatin architecture with gene regulation [42] . SATB1 promotes tumor growth and metastasis by reprogramming chromatin organization and transcription profiles, and is highly expressed in a variety of cancers including breast cancer [18] , laryngeal squamous cell carcinoma [19] , endometrioid endometrial cancer [20] , hepatocellular carcinoma [21] , rectal cancer [22] , cutaneous malignant melanoma [23] , gastric cancer [24, 25] , ovarian cancer [26] , prostate cancer [27] , lung cancer [28] and glioma [29] . In tumor cells with high levels of SATB1, genes that promote tumor progression and metastasis were up-regulated, whereas genes that inhibit tumor metastasis were repressed [17] ; while silencing of SATB1 greatly reduced the invasive and metastatic capacity of cancer cells [43] . Thus SATB1 is required and essential for tumor growth/survival and metastasis, and downregulation or loss of SATB1 expression may impair sustained tumor growth and metastasis. These characteristics make SATB1 an attractive target for development of effective cancer vaccines against various types of cancer. Here, we have described an HLA-A*02 binding SATB1-derived epitope, SATB1 565-574 . This is, to our knowledge, the first report to identify and characterize a SATB1-derived epitope that is recognized by CD8 + T cells. Although SATB1 565-574 peptide-specific T cells recognized and killed HLA-A*02 + SATB1-expressing Jeko-1 and Skov-1 cells, however, they did not directly recognize the other two HLA-A*02 + SATB1 + breast cancer cells tested in this study including CAMA-1 and MDA-MB-231. These differences may arise from the different cell types harboring different sets of proteasomes [44] , thus leading to different repertoire of peptides associated with MHC-I in different cell types. Indeed, when CAMA-1 and MDA-MB-231 were pretreated with an inducer of immunoproteasomes-IFN-c, they could then be recognized by SATB1 565-574 peptidespecific T cells (Figure 4B ), suggesting that IFN-c may enhance induction of immunoproteasomes, thus leading to the correct presentation of SATB1 565-574 to the tumor cell surface for T cell scrutiny. The enhanced expression of HLA-A*02 on cell surface by IFN-c ( Figure S2 ) is another possibility that make treated tumor cells recognized by SATB1 565-574 peptide-specific T cells.
It should be noted that SATB1 is not only highly expressed in various types of malignant tumor, its expression was also detectable in thymocytes and progenitor cells including osteoblasts, the basal layer of the epidermis, amyloblasts, and embryonic stem cells [45] [46] [47] . These cells may be targeted by vaccine-induced SATB1-peptide specific CD8 + T cells. However, the fact that SATB1 565-574-specific T cell responses are easily induced in healthy donors as well as cancer patients, suggests that a high frequency of SATB1-specific CD8 + T cell precursors is present in the circulation, which indicates that anti-cancer vaccines targeting SATB1 may be safe and may not induce autoimmunity. Indeed, SATB1 565-574 peptide-specific T cells did not recognize autologous PBMC in vitro ( Figure 4A ). Furthermore, although SATB1 plays an important role during T cell differentiation, SATB1 565-574 -specific T cells did not recognize in vitro-differentiated Th cell subsets, including Th1, Th2 and Th17 cells ( Figure S3) . Besides, the peptide SATB1 565-574 -HLA-I complexes on the surface of normal cells may be too low to reach the threshold for T cell scrutiny; while in cancer cells, overexpression of SATB1 results in increased presentation of the peptide on the cell surface for T cell recognition. Thus, the difference in SATB1 expression on normal and malignant cells may explain the reason that SATB1-specific T cells in healthy donors do not cause autoimmunity, SATB1-targeted immunotherapy is expected to be safe to treat cancer patients. Nevertheless, the risk of autoimmunity induced by SATB1-targeted immunotherapy should be still considered in future clinic trials and impact of SATB1-specific T cells on developing T cells in vivo needs further exploration.
The FDA has recently approved a cancer vaccine, Sipuleucel-T, for the treatment of patients with advanced prostate cancer based on a phase III study [4] . Sipuleucel-T is prepared from autologous PBMCs containing antigen presenting cells that are incubated with a recombinant protein composed of a PAP linked to granulocytemacrophage colony-stimulating factor (GM-CSF). Sipuleucel-T presumably works in part by augmenting PAP-specific CD8 + T cell responses, further demonstrating the importance of tumor antigen-specific CD8 + T cells induced by cancer vaccines. So far, Sipuleucel-T is the first cellular immunotherapeutic agent approved by the FDA to be used for the treatment of cancer patients. The FDA approval of Sipuleucel-T as a therapeutic cancer vaccine not only validates the efficacy of cancer immunotherapy, but also provides a strong impetus in the field of cancer immunology [1] . Therefore, identification and development of more novel TAAs including SATB1 and peptide derivatives recognized by CTLs is definitely essential to facilitate the development of effective cancer vaccines. Although, a large number of human TAAs have been identified in melanoma and SATB1 565-574 -specific T cells. SATB1 565-574 -specific T cells were cultured in medium alone as a negative control (red column); To block HLA-dependent responses, either anti-HLA-I mAb (W6/32) or HLA-II mAb was added into cell cultures during incubation of SATB1 565-574 -specific T cells with Skov-1 (C) or Jeko-1 cells (D). Cells were incubated for 18 -24 hours, the IFN-c secretion in the supernatant was determined by ELISA assay. SATB1 565-574 -specific CD8 + T cells were tested for cytotoxicity against T2 cells pulsed with or without peptides (E), Skov-1 (F) and Jeko-1 (G) by the LDH assay. HLA-A*02 negative PC3 cells were used as a negative control in the LDH assay. Data from A-G are plotted as means 6 SD. Results are representative of three independent experiments. *P,0.05, **P,0.01, ***P,0.001 versus controls. doi:10.1371/journal.pone.0056730.g004
other types of cancer [2] , much less is known about ovarian and lymphoma tumor antigens, thus impeding the development of cancer immunotherapy for patients with ovarian cancer and lymphoma. In this study, we find that SATB1 is also highly expressed in ovarian cancer cells and lymphoma cells, and importantly SATB1-specific T cells can recognize and kill these cancer cells, suggesting that identification of SATB1 as a tumor antigen has important implications for the development of potentially therapeutic vaccines against ovarian cancer, lymphoma and other types of cancer as well.
In summary, we have identified a novel SATB1-derived CD8 + T cell epitope SATB1 [565] [566] [567] [568] [569] [570] [571] [572] [573] [574] . Since SATB1 expression is strongly up-regulated in various types of cancer, SATB1 565-574 may serve as a diagnostic tool or an immunotherapeutic target of cancer vaccines for ovarian cancer, lymphoma and other types of cancer.
Supporting Information
Figure S1 
